<DOC>
<DOCNO>EP-0626387</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Nucleosides and oligonucleotides with 2'-ether groups
</INVENTION-TITLE>
<CLASSIFICATIONS>C07H1910	C07H1904	C07H1900	C07H1914	C12Q168	C07H1920	C07H1906	C07H1916	C07H19067	C07H19167	G01N3350	C12Q168	G01N3350	C07H1923	A61K4900	C07H2100	C07H2102	A61K4900	C07H2100	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07H	C07H	C07H	C07H	C12Q	C07H	C07H	C07H	C07H	C07H	G01N	C12Q	G01N	C07H	A61K	C07H	C07H	A61K	C07H	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07H19	C07H19	C07H19	C07H19	C12Q1	C07H19	C07H19	C07H19	C07H19	C07H19	G01N33	C12Q1	G01N33	C07H19	A61K49	C07H21	C07H21	A61K49	C07H21	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Compounds of the formula 
<
IMAGE
>
 in which R1 and R2 are, independently of one another, hydrogen or a protective group, or R1 has these meanings and R2 is a radical forming a phosphorus-containing nucleotide bridging group; B is a purine or pyrimidine residue or an analogue thereof; and R3 is a radical of the formula Ia, Ib or Ic 
<
IMAGE
>
 in which R4 is hydrogen, C1-C21-alkyl, C2-C21-alkenyl, C2-C21- alkynyl or -C(=O)-alkyl; R5 is hydrogen, C1-C10-alkyl, -CH2-O-R6 or a radical of the formula Ib; R6 is hydrogen, C1-C22-alkyl, C3-C21-alkenyl, partially or completely fluorine-substituted C1-C10-alkyl or -[(CH2)2-O]m-R7; R 7 is hydrogen or C1-C21-alkyl; Z is -(CH2)p- or -(CH2-CH-O)q-CH2 CH2-, where Z can in the case of -CH2- be unsubstituted or substituted by one or more C1-C10-alkyl, C5-C6-cycloalkyl or unsubstituted or C1-C4-alkyl-substituted phenyl, independently of one another; n is a number from 1 to 12; m is a number from 1 to 4; p is a number from 1 to 10; and q is a number from 1 to 4, are described.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
NOVARTIS AG
</APPLICANT-NAME>
<APPLICANT-NAME>
NOVARTIS ERFIND VERWALT GMBH
</APPLICANT-NAME>
<APPLICANT-NAME>
NOVARTIS AG
</APPLICANT-NAME>
<APPLICANT-NAME>
NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
MARTIN PIERRE DR
</INVENTOR-NAME>
<INVENTOR-NAME>
MARTIN, PIERRE, DR.
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
A compound of formula I


wherein

R
1
 and R
2
are each independently of the other hydrogen or a protecting group, or R
1
 has
those definitions and R
2
 is a radical forming a phosphorus-containing nucleotide
bridge group;
B
is a purine or pyrimidine radical or an analogue thereof; and
R
3
is a radical of formula Ia, Ib or Ic


wherein
R
4
is hydrogen, C
1
-C
21
alkyl, C
2
-C
21
alkenyl, C
2
-C
21
alkynyl or -C(=O)-alkyl;
R
5
is hydrogen, C
1
-C
10
alkyl, -CH
2
-O-R
6
 or a radical of formula Ib;
R
6
is hydrogen C
1
-C
22
alkyl, C
3
-C
21
 alkenyl or partially or completely fluorine-substituted
C
1
-C
10
alkyl or -[(CH
2
)
2
-O]
m
-R
7
;
R
7
is hydrogen or C
1
-C
21
alkyl;
Z
is -(CH
2
)
p
- or -(CH
2
-CH
2
-O)
q
-CH
2
CH
2
-, it being possible for Z in the case of -CH
2
-
to be unsubstituted or substituted by one or more identical or different substituents

selected from C
1
-C
10
alkyl, C
5
-C
6
cycloalkyl and unsubstituted or C
1
-C
4
alkyl-substituted
phenyl;
n
is number from 1 to 12;
m
is a number from 1 to 4;
p
is a number from 1 to 10; and
q
is a number from 1 to 4;
 
and R
4
 is not hydrogen when n = 1 and R
5
 = hydrogen.
A compound according to claim 1 wherein R
1
 and R
2
 are each hydrogen.
A compound according to claim 1 wherein R
1
 and R
2
 are identical protecting groups.
A compound according to claim 1 wherein B as a purine radical or an analogue thereof
is a radical of formula II, IIa, IIb, IIC, IId, IIe or IIf



wherein

R
b1
is H, Cl, Br, OH or -O-C
1
-C
12
alkyl, and
R
b2
, R
b3
 and R
b5
are each independently of the others H, OH, SH, NH
2
, NHNH
2
, NHOH, 
NHO-C
1
-C
12
alkyl, -N=CH-N(C
1
-C
12
alkyl)
2
, -N=CH-N-cycloalkyl, F, Cl, Br, C
1
-C
12
alkyl,
hydroxy-C
1
-C
12
alkyl , amino-C
1
-C
12
alkyl, C
1
-C
12
alkoxy, benzyloxy or C
1
-C
12
alkylthio,
the hydroxy and amino groups being unsubstituted or substituted by a

protecting group; or phenyl, benzyl, primary amino having from 1 to 20 carbon atoms
or secondary amino having from 2 to 30 carbon atoms,
R
b4
is hydrogen, CN or -C≡C-R
b7
, and
R
b6
 and R
b7
are hydrogen or C
1
-C
4
alkyl.
A compound according to claim 4 wherein the protecting group for hydroxy and amino
groups is C
1
-C
8
acyl.
A compound according to claim 4 wherein the primary amino contains from 1 to 12
carbon atoms and the secondary amino contains from 2 to 12 carbon atoms.
A compound according to claim 4 wherein the primary amino and the secondary amino
are radicals of the formula R
a1
R
a2
N, wherein R
a1
 is hydrogen or, independently, has the
definition of R
a2
, and R
a2
 is C
1
-C
20
alkyl, C
1
-C
20
aminoalkyl or C
1
-C
20
hydroxyalkyl;
carboxyalkyl or carbalkoxyalkyl, the carbalkoxy group containing from 2 to 8 carbon

atoms and the alkyl group from 1 to 6, preferably from 1 to 4, carbon atoms; C
2
-C
20
alkenyl;
phenyl, mono- or di-(C
1
-C
4
alkyl or C
1
-C
4
alkoxy)phenyl, benzyl, mono- or di-(C
1
-C
4
alkyl
or C
1
-C
4
alkoxy)benzyl; or 1,2-, 1,3- or 1,4-imidazolyl-C
1
-C
6
alkyl, or R
a1
 and
R
a2
 together are tetra- or penta-methylene, 3-oxa-1,5-pentylene, -CH
2
-NR
a3
-CH
2
CH
2
- or
-CH
2
CH
2
-NR
a3
-CH
2
CH
2
-, wherein R
a3
 is hydrogen or C
1
-C
4
alkyl; the amino group in
aminoalkyl being unsubstituted or substituted by one or two C
1
-C
4
alkyl or C
1
-C
4
hydroxyalkyl
groups, and the hydroxy group in hydroxyalkyl being unsubstituted or etherified by

C
1
-C
4
alkyl.
A compound according to claim 6 wherein the primary amino and the secondary amino
are methyl-, ethyl-, dimethyl-, diethyl-, allyl-, mono- or di-(hydroxy-eth-2-yl)-, phenyl-

and benzyl-, acetyl-, isobutyryl- and benzoyl-amino.
A compound according to claim 4 wherein R
b1
 in formulae II, IIb, IIc, IId and IIe is
hydrogen.
A compound according to claim 4 wherein R
b5
 in formula IId is hydrogen. 
A compound according to claim 4 wherein R
b2
 and R
b3
 in formulae II, IIa, IIb, IIc, IId
and IIf are, independently of one another, H, F, Cl, Br, OH, SH, NH
2
, NHOH, NHNH
2
,
methylamino, dimethylamino, benzoylamino, methoxy, ethoxy and methylthio.
A compound according to claim 4 wherein B is a purine radical or a radical of a purine
analogue from the series adenine, N-methyladenine, N-benzoyladenine, 2-methylthioadenine,

2-aminoadenine, 6-hydroxypurine, 2-amino-6-chloropurine, 2-amino-6-methylthiopurine,
guanine and N-isobutyrylguanine.
A compound according to claim 1 wherein B in formula I, as a pyrimidine radical, is a
uracil, thymine or cytosine radical of formula III, IIIa, IIIb or IIIc



wherein R
b6
 is hydrogen or C
1
-C
4
alkyl and R
b8
 is H, OH, SH, NH
2
, NHNH
2
, NHOH,
NHO-C
1
-C
12
alkyl -N=CH-N(C
1
-C
12
alkyl)
2
, -N=CH-N-cycloalkyl, F, Cl, Br, C
1
-C
12
alkyl,
hydroxy-C
1
-C
12
alkyl, amino-C
1
-C
12
alkyl, C
1
-C
12
alkoxy, benzyloxy or C
1
-C
12
alkylthio,
the hydroxy and amino groups being unsubstituted or substituted by a protecting group, or

is phenyl, benzyl, primary amino having from 1 to 20 carbon atoms, secondary amino
having from 2 to 30 carbon atoms, C
1
-C
12
alkenyl or C
1
-C
12
alkynyl, and the NH
2
 group in
formula IIIb is unsubstituted or substituted by C
1
-C
6
alkyl, benzoyl or by a protecting
group; or a dihydro derivative of a radical of formula III, IIIa, IIIb or IIIc. 
A compound according to claim 13 wherein R
b8
 is hydrogen, C
1
-C
6
alkyl or C
1
-C
6
-hydroxyalkyl,
C
2
-C
6
alkenyl or C
2
-C
6
alkynyl, F, Cl, Br, NH
2
, benzoylamino or mono- or
di-C
1
-C
6
alkylamino.
A compound according to claim 13 wherein R
b8
 is hydrogen, C
1
-C
6
alkyl or C
1
-C
6
-alkoxy
or C
1
-C
6
hydroxyalkyl, C
2
-C
6
alkenyl or C
2
-C
6
alkynyl, F, Cl, Br, NH
2
, benzoyl-amino
or mono- or di-C
1
-C
6
alkylamino.
A compound according to claim 14 wherein R
b8
 is H, F, Cl, Br, NH
2
, NHCH
3
,
N(CH
3
)
2
, C
1
-C
4
alkyl, C
2
-C
4
alkenyl-(1) or C
2
-C
4
alkynyl-(1).
A compound according to claim 15 wherein R
b8
 is hydrogen, C
1
-C
4
alkyl, C
2
-C
4
alkenyl-(1),
C
2
-C
4
alkynyl-(1), NH
2
, NHCH
3
 or (CH
3
)
2
N.
A compound according to claim 1 wherein B as a radical of a pyrimidine analogue is
derived from uracil, thymine, cytosine, 5-fluorouracil, 5-chlorouracil, 5-bromouracil,

dihydrouracil, 5-methylcytosine, 5-propynyluracil and 5-propynylcytosine.
A compound according to claim 1 wherein R
2
 as a phosphorus-containing, nucleotide-bridge-group-forming
radical corresponds to formula P1 or P2



wherein

Y
a
is hydrogen, C
1
-C
12
alkyl, C
6
-C
12
aryl, C
7
-C
20
aralkyl, C
7
-C
20
alkaryl, -OR
b
, -SR
b
, -NH
2
,
primary amino, secondary amino, O
⊖
M
⊕
 or S
⊖
M
⊕
;
X
a
is oxygen or sulfur;
R
a
is hydrogen, M
⊕
, C
1
-C
12
alkyl, C
2
-C
12
alkenyl or C
6
-C
12
aryl, or the group R
a
O- is
N-heteroaryl-N-yl having 5 ring members and from 1 to 3 nitrogen atoms;
R
b
is hydrogen, C
1
-C
12
alkyl or C
6
-C
12
aryl; and
 
M
⊕
 is Na
⊕
, K
⊕
, Li
⊕
, NH
4
⊕
 or primary, secondary, tertiary or quaternary ammonium;
alkyl, aryl, aralkyl and alkaryl in Y
a
, R
a
 and R
b
 being unsubstituted or substituted by
alkoxy, alkylthio, halogen, -CN, -NO
2
, phenyl, nitrophenyl or halophenyl.
A compound according to claim 19 wherein R
a
 is β-cyanoethyl and Y
a
 is di(isopropyl)amino.
A compound according to claim 1 wherein R
3
 is a radical of formula Ia.
A compound according to claim 21 wherein n is a number from 1 to 8.
A compound according to claim 22 wherein n is a number from 1 to 6.
A compound according to claim 21 wherein R
4
 is hydrogen, C
1
-C
21
alkyl, C
2
-C
21
-alkenyl
or C
2
-C
21
alkynyl.
A compound according to claim 24 wherein R
4
 is hydrogen or C
1
-C
4
alkyl.
A compound according to claim 21 wherein R
5
 is hydrogen, C
1
-C
5
alkyl or -CH
2
-OH,
-CH
2
-O-C
1
-C
22
alkyl or -CH
2
-O-[(CH
2
)
2
-O]
m
-C
1
-C
10
alkyl wherein m is a number from
1 to 4.
A compound according to claim 26 wherein R
5
 is hydrogen, methyl or -CH
2
-OH,
-CH
2
-O-C
1
-C
22
alkyl or -CH
2
-O-[(CH
2
)
2
-O]
m
-C
1
-C
10
alkyl wherein m is a number from
1 to 4.
A compound according to claim 1 wherein R
3
 is a radical of formula Ib.
A compound according to claim 28 wherein Z is -CH
2
- or substituted -CH
2
-.
A compound according to claim 1 wherein R
3
 is a radical of formula Ic.
A process for the preparation of a compound of formula I 


wherein R
1
 and R
2
 are each independently of the other hydrogen or a protecting group or
R
1
 has those definitions and R
2
 is a radical forming a phosphorus-containing nucleotide
bridge group; B is a purine or pyrimidine radical or an analogue thereof; and


(a) R
3
 is a radical of formula Ia


wherein

R
4
is hydrogen, C
1
-C
21
alkyl, C
2
-C
21
alkenyl, C
2
-C
21
alkynyl or -C(=O)-alkyl;
R
5
is hydrogen, C
1
-C
10
alkyl, -CH
2
-O-R
6
 or a radical of formula Ib;
R
6
is hydrogen, C
1
-C
22
alkyl, C
3
-C
21
alkenyl, partially or completely fluorine-substituted
C
1
-C
10
alkyl or -[(CH
2
)
2
-O]
m
-R
7
;
R
7
is hydrogen or C
1
-C
21
alkyl;
n
is a number from 1 to 12; and
m
is a number from 1 to 4;

and R
4
 is not hydrogen when n = 1 and R
5
 = hydrogen,

which process comprises

reacting a compound of formula IVa


wherein R
14
 and R
15
 are identical or different protecting groups and B is a purine or
pyrimidine radical or an analogue thereof, functional groups in the base radical B being

protected by protecting groups, in an inert solvent, with a compound of formula A 


wherein R
4
, R
5
 and n are as defined above and X is Cl, Br, I, tosyl-O or mesyl-O;
(b) R
3
 is a radical of formula Ic


which process comprises reacting a compound of formula IVa in an inert solvent with a
compound of formula B



wherein X is Cl, Br, I, tosyl-O or mesyl-O;
(c) R
3
 is a radical of formula Ib


wherein

R
5
is hydrogen, C
1
-C
10
alkyl, -CH
2
-O-R
6
 or a radical of formula Ib;
R
6
is hydrogen, C
1
-C
22
alkyl, C
3
-C
21
alkenyl, partially or completely fluorine-substituted
C
1
-C
10
alkyl or -[(CH
2
)
2
-O]
m
-R
7
;
R
7
is hydrogen or C
1
-C
21
alkyl;
Z
is -(CH
2
)
p
- or -(CH
2
-CH-O)
q
-CH
2
CH
2
-, it being possible for Z in the case of -CH
2
- to
be unsubstituted or substituted by one or more identical or different substituents

selected from C
1
-C
10
alkyl, C
5
-C
6
cycloalkyl and unsubstituted or C
1
-C
4
alkyl-substituted
phenyl;
m
is a number from 1 to 4;
p
is a number from 1 to 10; and 
q
is a number from 1 to 4;

which process comprises opening the epoxide obtained in (b) in the presence of H
2
O and
BF
3
 and closing it with a compound of formula X'-(CH
2
)
q
-X' or X
'
-(CH
2
-CH-O)
r
-X',
wherein X' is Cl, Br, I, tosyl-O or mesyl-O, to form a new ring;
(d) R
3
 is a radical of formula Ia,

which process comprises reacting the epoxide obtained in (b) in the presence of R
6
OH and
BF
3
 and, where appropriate, converting the freed hydroxy group into an ether or an ester;
(e) R
3
 is a radical of formula Ia,

which process comprises hydrogenating the epoxide obtained in (b) in the presence of BF
3

and, for example, NaBH
4
, and, where appropriate, converting the freed hydroxy group into
an e
ther or an ester;
(f) R
3
 is a radical of formula Ia,

which process comprises reacting the epoxide obtained in (b) with a suitable Grignard
reagent and, where appropriate, converting the freed hydroxy group into an ether or an

ester; or
g) R
3
 is a radical of formula Ia, Ib or Ic,

which process comprises substituting at the 2'-OH group by one of the processes
described in (a) to (f) a compound of formula IVb



wherein R
14
 and R
15
 are as defined above and A is a leaving group, and introducing the
base radical B by substitution; where appropriate removing the protecting groups R
14
 and
R
15
, and introducing the radical forming a phosphorus-containing nucleotide bridge group.
The use of a compound according to claim 1 in the preparation of oligonucleotides
comprising identical or different monomer units of compounds of formula I or comprising

at least one monomer unit of compounds of formula I in combination with monomer units 
of other natural or synthetic nucleosides, the oligonucleotides consisting of from 2 to

200 monomer units.
The use according to claim 32 in the preparation of oligonucleotides having from 2 to
100 monomer units.
The use according to claim 33 in the preparation of oligonucleotides having from 2 to
50 monomer units.
The use according to claim 34 in the preparation of oligonucleotides having from 4 to
30 monomer units.
The use according to claim 32 in the preparation of oligonucleotides having identical
or different monomer units of compounds of formula I.
The use according to claim 32 in the preparation of oligonucleotides having identical
monomer units of compounds of formula I and monomer units of natural or synthetic

nucleosides.
An oligonucleotide of formula V

5'-U-(O-Y-O-V-)
x
O-Y-O-W-3'

wherein x is a number from 0 to 200 and Y is a nucleotide bridge group; U, V and W are,
each individually, identical or different radicals of natural or synthetic nucleosides, and at

least one of the radicals U, V and/or W is a radical of formula VI


wherein B is a purine or pyrimidine radical or an analogue thereof; and R
3
 is a radical of
formula Ia, Ib or Ic 



wherein

R
4
is hydrogen, C
1
-C
21
alkyl, C
2
-C
21
alkenyl, C
2
-C
21
alkynyl or -C(=O)-alkyl;
R
5
is hydrogen, C
1
-C
10
alkyl, -CH
2
-O-R
6
 or a radical of formula Ib;
R
6
is hydrogen, C
1
-C
22
alkyl, C
3
-C
21
alkenyl, or partially or completely fluorine-substituted
C
1
-C
10
alkyl or -[(CH
2
)
2
-O]
m
-R
7
;
R
7
is hydrogen or C
1
-C
21
alkyl;
Z
is -(CH
2
)
p
- or -(CH
2
-CH
2
-O)
q
-CH
2
CH
2
-, it being possible for Z in the case of -CH
2
-
to be unsubstituted or substituted by one or more identical or different substituents

selected from C
1
-C
10
alkyl, C
5
-C
6
cycloalkyl and unsubstituted or C
1
-C
4
alkyl-substituted
phenyl;
n
is a number from 1 to 12;
m
is a number from 1 to 4;
p
is a number from 1 to 10; and
q
is a number from 1 to 4.
An oligonucleotide according to claim 38 wherein the bridge group Y is -P(O)O
⊖
-,
-P(O)S
⊖
-, -P(S)S
⊖
-, -P(O)R
16
-, -P(O)NR
17
R
18
- or -CH
2
-, wherein R
16
 is hydrogen or
C
1
-C
6
alkyl, and R
17
 and R
18
, each independently of the other, have the definition of R
16
.
An oligonucleotide according to claim 38 wherein the bridge group Y is -P(O)O
⊖
-.
An oligonucleotide according to claim 38 wherein x is a number from 0 to 100.
An oligonucleotide according to claim 41 wherein x is a number from 1 to 50.
An oligonucleotide according to claim 42 wherein x is a number from 3 to 29.
An oligonucleotide according to claim 38 wherein the radicals of formula VI are
bonded terminally and/or in the nucleotide sequence. 
An oligonucleotide according to claim 38 wherein the radicals of formula VI are
bonded between radicals of natural or synthetic nucleosides.
An oligonucleotide according to claims 44 and 45 wherein from 2 to 5 identical or
different radicals of formula VI follow one another.
An oligonucleotide according to claim 38 comprising a total of from 4 to 30 nucleoside
units and from 1 to 12 radicals of formula VI.
An oligonucleotide according to claim 38 wherein B as a purine radical or as an
analogue thereof is a radical of formula II, IIa, IIb, IIc, IId, IIe or IIf


 
wherein


R
b1
is H, Cl, Br, OH or -O-C
1
-C
12
alkyl, and
R
b2
, R
b3
 and R
b5
are each independently of the others H, OH, SH, NH
2
, NHNH
2
, NHOH,
NHO-C
1
-C
12
alkyl, -N=CH-N(C
1
-C
12
alkyl)
2
, -N=CH-N-cycloalkyl, F, Cl, Br, C
1
-C
12
-alkyl,
hydroxy-C
1
-C
12
alkyl, amino-C
1
-C
12
alkyl, C
1
-C
12
alkoxy, benzyloxy or C
1
-C
12
-alkylthio,
the hydroxy and amino groups being unsubstituted or substituted by a

protecting group; or phenyl, benzyl, primary amino having from 1 to 20 carbon atoms
or secondary amino having from 2 to 30 carbon atoms,
R
b4
is hydrogen, CN or -C≡C-R
b7
, and
R
b6
 and R
b7
are hydrogen or C
1
-C
4
alkyl.
An oligonucleotide according to claim 38 wherein B is a uracil, thymine or cytosine
radical of formula III, IIIa, IIIb or IIIc



wherein R
b6
 is hydrogen or C
1
-C
4
alkyl and R
b8
 is H, OH, SH, NH
2
, NHNH
2
, NHOH,
NHO-C
1
-C
12
alkyl, -N=CH-N(C
1
-C
12
alkyl)
2
, -N=CH-N-cycloalkyl, F, Cl, Br, C
1
-C
12
alkyl,
hydroxy-C
1
-C
12
alkyl, amino-C
1
-C
12
alkyl, C
1
-C
12
alkoxy, benzyloxy or C
1
-C
12
alkylthio,
the hydroxy and amino groups being unsubstituted or substituted by a protecting group, or

is phenyl, benzyl, primary amino having from 1 to 20 carbon atoms, secondary amino
having from 2 to 30 carbon atoms, C
1
-C
12
alkenyl or C
1
-C
12
alkynyl, and the NH
2
 group in
formula IIIb is unsubstituted or substituted by C
1
-C
6
alkyl, benzoyl or by a protecting 
group; or a dihydro derivative of a radical of formula III, IIIa, IIIb or IIIc.
An oligonucleotide according to claim 38 wherein R
3
 is a radical of formula Ia.
An oligonucleotide according to claim 50 wherein n is a number from 1 to 8.
An oligonucleotide according to claim 51 wherein n is a number from 1 to 6.
An oligonucleotide according to claim 50 wherein R
4
 is hydrogen, C
1
-C
21
alkyl,
C
2
-C
21
alkenyl or C
2
-C
21
alkynyl.
An oligonucleotide according to claim 53 wherein R
4
 is hydrogen or C
1
-C
4
alkyl.
An oligonucleotide according to claim 50 wherein R
5
 is hydrogen, C
1
-C
5
alkyl or
-CH
2
-OH, -CH
2
-O-C
1
-C
22
alkyl or -CH
2
-O-[(CH
2
)
2
-O]
m
-C
1
-C
10
alkyl, wherein m is a
number from 1 to 4.
An oligonucleotide according to claim 55 wherein R
5
 is hydrogen, methyl or
-CH
2
-OH, -CH
2
-O-C
1
-C
22
alkyl or -CH
2
-O-[(CH
2
)
2
-O]
m
-C
1
-C
10
alkyl, wherein m is a
number from 1 to 4.
An oligonucleotide according to claim 38 wherein R
3
 is a radical of formula Ib.
An oligonucleotide according to claim 57 wherein Z is -CH
2
- or substituted -CH
2
-.
An oligonucleotide according to claim 38 wherein R
3
 is a radical of formula Ic.
The use of an oligonucleotide of formula V according to claim 38 as a diagnostic agent
in the detection of viral infections or genetic diseases.
An oligonucleotide of formula V according to claim 38 for use in a therapeutic method
for the treatment of diseases in warm-blooded animals, including humans, by interaction

with nucleotide sequences in the body.
A pharmaceutical composition comprising an effective amount of a nucleotide of 
formula I according to claim 1 or of an oligonucleotide of formula V according to claim

38 alone or together with other active ingredients, a pharmaceutical carrier and, where
appropriate, excipients.
A compound according to claim 21, wherein

n is an integer from 1 to 3,
R
4
 is hydrogen, methyl or acetyl, and
R
5
 is hydrogen, methyl or -CH
2
OH.
A compound according to claim 63, wherein n = 1, R
4
 is acetyl and R
5
 is hydrogen.
A compound according to claim 63, wherein n = 1, R
4
 is methyl and R
5
 is hydrogen.
A compound according to claim 63, wherein n = 1, R
4
 is methyl and R
5
 is methyl.
A compound according to claim 63, wherein n = 1, R
4
 is hydrogen and R
5
 is -CH
2
OH.
A compound according to claim 63, wherein n = 3, R
4
 is methyl and R
5
 is hydrogen.
An oligonucleotide according to claim 50, wherein

n is an integer from 1 to 3,
R
4
 is hydrogen, methyl or acetyl, and
R
5
 is hydrogen, methyl or -CH
2
OH.
An oligonucleotide according to claim 69, wherein n = 1, R
4
 is acetyl and R
5
 is
hydrogen.
An oligonucleotide according to claim 69, wherein n = 1, R
4
 is methyl and R
5
 is
hydrogen.
An oligonucleotide according to claim 69. wherein n = 1, R
4
 is methyl and R
5
 is
methyl.
An oligonucleotide according to claim 69, wherein n = 1, R
4
 is hydrogen and R
5
 is
-CH
2
OH. 
An oligonucleotide according to claim 69, wherein n = 3, R
4
 is methyl and R
5
 is
hydrogen.
</CLAIMS>
</TEXT>
</DOC>
